Business
4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
• 24-week injection-free subgroup analyses from the Randomized Phase 2 Dose Expansion Stage of PRISM Trial Evaluating 4D-150 in wet AMD patients with severe
About this update from 4d Molecular Therapeutics, Inc.
[{"type":"text","content":"• 24-week injection-free subgroup analyses from the Randomized Phase 2 Dose Expansion Stage of PRISM Trial Evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden to be presented in oral presentation\nEMERYVILLE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced presentations at the Clinical Trials at the Summit (CTS) Meeting in Park City, Utah on June 8, 2024. CTS 2024 Meeting Presentation Details Panel:Designing Registration Trials with the Latest FDA GuidanceTime:1:49-2:09 p.m. MDTPanelist:Robert Kim, M.D., Chief Medical Officer, 4DMT Scientific Presentation:24-week Results from the Randomized Phase 2 Dose Expansion Stage of PRISM Trial Evaluating 4D-150 in High Need nAMD PatientsSession:Gene Therapy and OptogeneticsTime:2:16-2:20 p.m. MDTPresenter:Carl Danzig, M.D., Rand Eye Institute, Deerfield Beach, FL Sponsor Talk:4DMT Corporate OverviewTime:2:53-2:58 p.m. MDTPresenter:David Kirn, M.D., Co-founder and CEO, 4DMT Panel:Challenges of Bringing New Treatment Options to MarketTime:3:40-4:00 p.m. MDTPanelist:David Kirn, M.D., Co-founder and CEO, 4DMT The 4D-150 presentation will also be available on the 4DMT website: https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications About 4DMT 4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases in ophthalmology, pul...